Eisai Co., Ltd., Eisai Corp. of North America (ECA), has signed a definitive agreement to acquire Morphotek, Inc. for $325 million in cash. Morphotek develops therapeutic monoclonal antibodies through the use of proprietary human antibody technologies, including Human Morphodoma and Libradoma. The company is using these technologies to enrich its pipeline that includes therapeutic antibody leads for the treatment of cancer, rheumatoid arthritis, and infectious disease. Two of its programs a...